ESMO 2022: Sacituzumab Govitecan for Patients With HR-Positive HER2-Negative Metastatic Breast Cancer
Posted: 10/05/2022 | By: Chase Doyle

The second interim analysis of the TROPiCS-02 trial—which studied the efficacy of the TROP2–directed antibody-drug conjugate sacituzumab govitecan-hziy in patients with hormone receptor (HR)-positive/HER2-negative locally recurrent inoperable or metastatic breast cancer—were presented at the European Society for Medical Oncology (ESMO) Congress 2022 (Abstract LBA76).

Question 1 of 5

In the first interim analysis of the phase III TROPiCS-02 study, patients with hormone receptor (HR)-positive/HER2-negative metastatic breast cancer who were randomly assigned to receive sacituzumab govitecan-hziy vs treatment of physician's choice had a progression-free survival benefit of how many months?

Choose 1